SCHEDULE 1

Marketing authorisations **[**F1in Great Britain**][**F1in Northern Ireland**]**

Textual Amendments

F1 Words in Sch. 1 heading inserted (E.W.S.) (31.12.2020) by The Veterinary Medicines and Residues (Amendment) (EU Exit) Regulations 2020 (S.I. 2020/1461), regs. 1(2)(b), **4(7)(a)**

F1 Words in Sch. 1 heading inserted (N.I.) (31.12.2020) by The Animals (Health, Identification, Trade and Veterinary Medicines) (Amendment) (EU Exit) Regulations (Northern Ireland) 2020 (S.R. 2020/353), regs. 1(3), **10(13)(a)**

PART 2

Derogations from some of the requirements in Part 1

Similar immunological products

[F1**15.** Where an immunological veterinary medicinal product is pharmacologically equivalent to a reference product other than differences in raw materials or in the manufacturing process, the results of the appropriate pre-clinical tests or clinical trials must be provided, but the applicant need not provide the results of safety tests or residue tests.**]**

Textual Amendments

F1 Sch. 1 para. 15 omitted (E.W.S.) (17.5.2024) by virtue of The Veterinary Medicines (Amendment etc.) Regulations 2024 (S.I. 2024/567), regs. 1(1), **40**

Changes to legislation:
There are currently no known outstanding effects for the The Veterinary Medicines Regulations 2013, Paragraph 15.